Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Varicella vaccine is a live-attenuated viral vaccine designed to prevent chickenpox, an infectious disease caused by the varicella-zoster virus (VZV). The vaccine is typically derived from the Oka strain of VZV, which was originally isolated in Japan and attenuated through serial passage in cell cultures. It works by stimulating the production of VZV-specific antibodies and T-cell responses, providing long-term immunity. While primarily used in pediatric populations, it is also indicated for susceptible adults and healthcare workers. In the context of clinical research, such as studies conducted at Hôpital Foch, the virus is also the subject of serological testing to evaluate immunity levels in specific populations like pregnant women to guide post-partum vaccination strategies.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on varicella vaccine.